ClinicalTrials.gg
RecruitingNCT07593404DRAGONUpdated Nov 16, 2026

Evaluation of a Novel Ocular Lubricating Eye Drop

An interventional study of Part 2 ABR2 At least twice a day for 28 days and Part 1: ABR2 single dose in one eye in Dry Eye Syndrome (DES), sponsored by Pleryon Therapeutics (Hangzhou) Limited. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Pleryon Therapeutics (Hangzhou) Limited · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.
Updated Nov 16, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 45 studies in Dry Eye Syndromes with a site in Canada — 5 open to participants now, 5 under way, 1 of them phase 3. Dry Eye Syndromes · Canada.

Planned enrollment
23rd of 37
40 · median 48
Started
2026
with 1 other
No phase
21 of 45
1 open now
Registered
45th of 45
by date

Among the 45 studies in Dry Eye Syndromes with a site in Canada, this one is the 23rd largest by planned enrollment of the 37 interventional ones that give a count, is one of 2 that started in 2026, is one of 21 with no phase, and was the 45th registered.

Dry Eye Syndromes

1,370 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

5 of the 45 studies in Dry Eye Syndromes with a site in Canada are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 117 Dry Eye Syndromes studies recruiting now, 74 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Dry Eye Syndromes with a site in Canada, or all of them as a file.
02

Study summary

The objective of this 2-part study is to assess the safety and tolerability of the new ocular lubricating drop ABR2 during short-term use in subjects for the temporary relief of ocular discomfort due to dryness of the eye.

In Part 1, participant will receive 1 drop of ABR2 in one eye and through assessments over a 1-hour period.

In Part 2, participant will use 1 drop of ABR2 at least two times a day for 28-day period (may use up to 4 times a day as needed) This is a single arm, open label study with no placebo or comparative arm.

Read the detailed description

Part 1 has a total of 2 scheduled visits, including Screening and Treatment visit. Participants will attend Part 1 for a total of 3.0 hours.

Part 2 has a total of 6 scheduled visits, including the Screening, baseline \& dispense visit, day 3, 1-week, 2-week, and 4-week Follow Up. Participants will attend Part 2 for a total of 6.5 hours.

03

Conditions studied

  • Dry Eye Syndrome (DES)

Browse trials for

Keywords

  • dry eye syndrome
  • ophthalmic solution
  • lubrication
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Are at least 18 years of age and have capacity to volunteer
  2. Are able to read (Part 2 only);
  3. Have signed an information and consent letter;
  4. Are willing to follow instructions and maintain the appointment schedule;
  5. Are willing to refrain from contact lens wear throughout the study period;
  6. Have a best corrected visual acuity of +0.20 LogMAR or better in each eye;
  7. Have an OSDI score ≥13 AND at least one of the following signs in at least one eye: Non-invasive tear film break-up time (NITBUT) \< 10 sec, AND/OR ocular surface staining (> 5 corneal spots, and/ or > 9 conjunctival spots)

Exclusion criteria

Exclusion Criteria:

  1. Participation in another ocular clinical research study or pharmaceutical clinical study within the past 14 days;
  2. Have a known active ocular disease and/ or infection with the exception of dry eye disease;
  3. Have any slit lamp findings that would contraindicate use of the study product;
  4. Have a systemic condition that would contraindicate use of the study product;
  5. Are using any systemic or topical medications that in the opinion of the investigator may affect a study outcome variable;
  6. Have undergone refractive error surgery or intraocular surgery within the last 12 months;
  7. Have any known sensitivity or allergy to the diagnostic sodium fluorescein or to any ingredients in the study product;
  8. Are using ocular lubricating eye drops more than twice per day on a typical day over the past month (Part 2 only);
  9. Are an employee of the Centre for Ocular Research \& Education directly involved in this study
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Part 1

    Part 1 Participants

    Drug: Part 1: ABR2 single dose in one eye

  • Experimental
    Part 2

    Part 2 Participants

    Drug: Part 2 ABR2 At least twice a day for 28 days

Interventions

  • DrugPart 2 ABR2 At least twice a day for 28 days

    Use ABR2 at least BID, up to QID for 28 days

  • DrugPart 1: ABR2 single dose in one eye

    Receive a single dose in one eye only

06

What researchers measure

Primary outcomes

  1. Number of Adverse Events

    Number of adverse events associated with the use of ocular eye drop. Example of adverse events may include, severe conjunctival and palpebral hyperemia, hypersensitivity, allergic reaction, eyelid edema, and photophobia.

    Time frame: At the end of Part 1: 60 minutes after single drop monocular instillation and At the end of Part 2 (after 28 days of bilateral use)

Other outcomes

  1. Subjective Ratings of Ocular Comfort, Stinging/Burning Sensation and Vision

    Participants will be asked to provide subjective ratings of ocular comfort, stinging/burning sensation and vision based on 0-100 rating scale.

    Time frame: Part 1: Immediately after drop instillation, 10 minutes, 30 minutes and 60 minutes post drop instillation. Part 2: Upon waking and at the end of day weekly for 4 weeks (Home Questionnaire)

  2. Signs of ocular dryness - Non-invasive tear film break up time (NITBUT)

    Non-invasive tear film break up time (NITBUT) will be performed to examine signs of ocular dryness.

    Time frame: Part 1: Baseline and 60 minutes after a drop of ABR2 application. Part 2: Baseline, 2 week, and 4 week after ABR2 use

  3. High Contrast High Luminance (HCHI) LogMAR Visual Acuity

    Monocular and binocular HCHI VA

    Time frame: Part 1: Baseline, immediate, 5 minutes, 10 minutes, 30 minutes and 60 minutes after drop application Part 2: Baseline, day 3, 1-week, 2-week and 4-week follow up

07

Study locations

1 of 1 sites recruiting
  • Centre for Ocular Research & Education, School of Optometry & Vision Science, University of Waterloo
    Waterloo, Ontario N2L 3G1, Canada
    Recruiting
08

References and documents

Related links

Individual participant data

Plan to share: No — Small sample size re-identification risk and limited infrastructure for external data access.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Nov 2026, 6 months after the start.

Of 115 industry-sponsored interventional studies with no phase under Dry Eye Syndromes, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 14. This study's planned 6 months is below that.

Counting every sponsor, half of 315 studies reached it within 10 months; a quarter within 4 and three quarters within 18.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Jan 2027 → Nov 2026 and completion May 2027 → Feb 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2026
First posted
May 18, 2026
StartActual
May 28, 2026
Primary completionEst.
Nov 2026was Jan 2027
CompletionEst.
Feb 2027was May 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jan 2027→Nov 2026
Nov 16, 2026
Study completion
May 2027→Feb 2027
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Primary completion Jan 2027→Nov 2026
    Study completion May 2027→Feb 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07593404
Lead sponsor
Pleryon Therapeutics (Hangzhou) Limited
Collaborators
University of Waterloo
Responsible party
Sponsor
First posted
May 18, 2026
Start date
May 28, 2026
Primary completion
Nov 2026 (estimated)
Completion
Feb 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

CORE Studies
Contact
corestudies@uwaterloo.ca
519-888-4742
Ulli Stahl, PhD
Contact
ustahl@uwaterloo.ca
519-888-4742
Charis Lau, PharmD, OD
study chair · Pleryon Therapeutics
Jill Woods, MSc, MCOptom
principal investigator · Centre for Ocular Research & Education, University of Waterloo

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion